Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits.

ABSTRACT: Multiple sclerosis (MS) is a chronic immunological disease of the central nervous system characterized by early inflammatory demyelination and subsequent neurodegeneration. Major therapeutic progress has occurred during the past decade, in particular since the introduction of immunomodulatory agents, however, MS is still an incurable disease. In addition, parenteral application of the currently licensed drugs is associated with injection-related adverse events (AEs) and low patient compliance. Thus, there remains an unmet need for the development of more effective and well tolerated oral therapies for the treatment of MS. A number of new orally administered agents including fingolimod, laquinimod, teriflunomide, cladribine, and BG-12 have been licensed recently or are currently under inves

SUBMITTER: Thone J 

PROVIDER: S-EPMC3585507 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature